Core Insights - Dow Inc.'s third-quarter earnings report showed mixed results compared to consensus estimates, yet the company's stock price surged by 13% [1] Company Performance - The surge in Dow Inc.'s stock price is attributed to the context of disappointing results from global chemical companies in recent quarters, making Dow's performance relatively more favorable [1] Investor Sentiment - Investors are increasingly focused on high-quality stocks and businesses with disciplined capital allocation, exceptional returns on capital, and the ability to compound invested capital over long periods [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Dow Inc. securities between January 30, 2025, and July 23, 2025, of the upcoming lead plaintiff deadline on October 28, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Dow securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 28, 2025 [2]. - The lawsuit alleges that Dow made false and misleading statements regarding its financial flexibility and the impact of macroeconomic factors on its business [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in handling significant cases [3].

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding the company's financial health and ability to manage macroeconomic challenges during the specified class period from January 30, 2025, to July 23, 2025 [1][4]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [4]. - It is alleged that the true impact of competitive pressures, declining global sales, and product oversupply on Dow's business was understated [4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which led to a stock price drop of over 3% [5]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [6]. - Following the disappointing Q2 results, Dow's stock price fell by more than 17%, and the company announced a dividend cut from $0.70 to $0.35 per share [6]. Group 2: Legal Process and Representation - Investors who purchased Dow securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [7]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [7]. Group 3: About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8]. - The firm has been recognized for obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [9].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the specified class period from January 30, 2025, to July 23, 2025 [3][7]. Allegation Details - Defendants overstated Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were understated [3]. - Public statements made by the defendants were materially false and misleading throughout the class period [3]. Next Steps - Investors who purchased Dow shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in complex litigation across various courts [5].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. on behalf of shareholders who purchased securities during the specified class period from January 30, 2025, to July 23, 2025 [1] Company Summary - Dow Inc. is identified as a materials science company [1] - The lawsuit is being led by Rosen Law Firm, which specializes in investor rights [1] Allegations Summary - The allegations under investigation by Rosen Law Firm pertain to the actions of Dow Inc. during the class period [1]

Group 1: Federal Reserve Policy Shift - The Federal Reserve is transitioning from prioritizing inflation control to focusing on growth, with a consensus expectation of interest rate cuts in October and December, indicating a potential continuous rate-cutting cycle [1] - This policy adjustment is driven by reduced inflation pressures and signs of weakness in the job market, rather than economic panic [1] Group 2: Impact on Pharmaceutical and Chemical Industries - The interest rate cuts will lower financing costs and improve global liquidity, significantly benefiting the pharmaceutical sector, especially innovative drug and CXO companies reliant on financing for R&D [3] - The pharmaceutical sector is expected to see increased capital flow towards emerging market assets, supported by recent policy events and conferences [3] - In contrast, the chemical industry may experience a replenishment cycle, stimulating capital expenditures and production investments, but faces challenges from rising raw material costs and weak global demand [3] Group 3: Company Performance Highlights - Sanofi expects high single-digit sales growth and low double-digit earnings per share growth driven by innovation, despite challenges in its vaccine business [4] - Roche reported a 7% year-on-year sales increase to 45.9 billion Swiss francs, primarily driven by its pharmaceutical division, which saw a 9% increase due to high demand for key innovative drugs [5] - Dow Inc. experienced an 8% year-on-year decline in net sales, with all operational segments showing a downturn, although cash flow improved significantly due to working capital optimization [5] Group 4: Trends in the Pharmaceutical and Chemical Sectors - Chinese companies are gaining global competitiveness in the pharmaceutical sector, particularly in the CXO field, which is becoming a crucial base for global pharmaceutical innovation [5] - Traditional sectors like raw material and chemical pharmaceuticals must upgrade technology and collaborate across the supply chain to avoid market share and profit erosion [5] - The future competitiveness of the global market and China's pharmaceutical and chemical industries will increasingly depend on technological innovation and global operational capabilities [6]

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 28, 2025 to file lead plaintiff applications in a securities class action lawsuit against Dow Inc. (NYSE: DOW), if they purchased the Company's securities between January 30, 2025 and July 23, 2025, inclusive (the "Class Period†). This action is pending in the United States District Court f. ...

Market Overview - The U.S. stock market reached unprecedented highs on October 24, 2025, with all three major indexes setting new records due to a cooler-than-expected inflation report, strong corporate earnings, and easing global trade tensions [1][3][9] - The S&P 500 climbed approximately 0.9% to 1%, surpassing the 6,800-point mark for the first time, while the Dow Jones Industrial Average rose around 1.1% or 519 points, and the Nasdaq Composite advanced approximately 1.3% to 1.31% [2] Sector Performance - The technology and semiconductor sectors were significant contributors to the market gains, with companies like Advanced Micro Devices (AMD) surging approximately 6.5% and Intel (INTC) seeing shares rise between 1.2% and 3.8% due to strong demand driven by the AI boom [4][12] - Energy stocks also performed well, boosted by rising crude oil prices following new U.S. sanctions on major Russian oil producers [4] - Defensive sectors such as consumer staples, healthcare, and utilities experienced modest movements or slight declines, indicating a "risk-on" market sentiment [4] Company News - Ford Motor (F) shares increased by 11.1% after reporting stronger-than-expected profits [7] - Dow Inc. led the S&P 500 with a jump of over 12% after exceeding consensus estimates for adjusted operating EBITDA in Q3 [12] - HCA Healthcare (HCA) saw its shares rise over 4% after significantly surpassing Q3 earnings expectations [12] - Conversely, Newmont Mining (NEM) fell 4.3% despite reporting stronger-than-expected profits, and Deckers Outdoor (DECK) plunged 12.5% to 14% after providing a weaker-than-expected outlook [12]

We recently published Why These 10 Stocks are Soaring by Double Digits. Dow Inc. (NYSE:DOW) is one of the best performers on Thursday. Shares of Dow Inc. (NYSE:DOW) climbed by 12.95 percent on Thursday to end at $24.51 apiece despite a dismal earnings performance in the third quarter of the year, as investors took heart from lower-than-expected losses. In an updated report, Dow Inc. (NYSE:DOW) clocked in a $0.19 loss per share, lower than the $0.30 as expected by analysts, on a net income of $124 million ...

SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Dow Inc. (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, all dates inclusive (the “Class Period”), have until this Tuesday, October 28, 2025 to seek appointment as lead plaintiff of the Dow class action lawsuit. Captioned Sarti v. Dow Inc., No. 25-cv-12744 (E.D. Mich.), the Dow class action lawsuit charges Dow, The Dow Chemical Company, a Dow subsidiary, and certain of D ...